Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

Original reporting
Published Oct 28, 2026, 7:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 7:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$GMAB
Bullish
high confidence
Mentioned
$GMAB · $LUNG · $AXGN · $KIDS · $REPL
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$GMABBullishHigh
01

Why it matters

Collective positive results suggest a short‑term sector rally, but individual company risks remain.

02

Market read

Each company’s fresh data drove a >25% price surge, offering immediate trading opportunities.

03

What to watch

Potential dilution from upcoming financing rounds or acquisition costs could temper upside.

Relevance 8/10Novelty 8/10Timing: same-day reaction

Background

A roundup of recent biotech earnings and trial updates, each triggering sizable intraday moves.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Genmab posted positive Phase 3 data for petosemtamab+Keytruda, driving a 33% share jump.

Expected impact

upward pressure as investors price in potential approval and market expansion

Evidence & confidence

Phase 3 results showing 50% mortality reduction are material and new, prompting a strong price move.

$LUNGBullishHigh confidence
Context

Pulmonx reported Q3 revenue growth and narrowed loss, raising its 2026 outlook, sending the stock up 33%.

Expected impact

upward as the market rewards higher revenue guidance and margin outlook

Evidence & confidence

Quarterly results and guidance lift investor confidence, a fresh catalyst.

$AXGNBullishHigh confidence
Context

Axogen posted strong Q3 revenue, profit and raised 2026 guidance, pushing the stock up 32%.

Expected impact

upward pressure from higher earnings and acquisition‑related growth expectations

Evidence & confidence

First‑report earnings with guidance raise are material for a small‑cap biotech.

$KIDSBullishHigh confidence
Context

OrthoPediatrics delivered record Q3 revenue and narrowed loss, raising its 2026 outlook, lifting the stock 29%.

Expected impact

upward as investors value improved profitability and higher guidance

Evidence & confidence

Fresh earnings and guidance are new, material information.

$REPLBullishHigh confidence
Context

Replimune narrowed its Q2 loss and reported cash runway, sending the stock up 25%.

Expected impact

upward as the market rewards lower loss and sufficient liquidity

Evidence & confidence

First‑report loss improvement and cash update are material for the stock.

Market effects

Biotech sector gains momentum as multiple companies report strong trial data and earnings, potentially lifting peers.

U.S. biotech indices likely see short‑term upside.

Limited to biotech investors; no broad macro impact.

Counterpoint

Some investors may wait for regulatory approval risk before adding positions.

Key entities

  • Genmab A/S

    Danish biotech developing antibody therapies.

  • Pulmonx Corporation

    Medical device maker focused on lung treatments.

  • Axogen, Inc.

    Developer of regenerative medicine products.

  • OrthoPediatrics Corp.

    Pediatric orthopedic device manufacturer.

  • Replimune Group, Inc.

    Immuno‑oncology biotech.

Related articles

$LUNGMed

Pulmonx Corporation: Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal System

Pulmonx Corporation (Nasdaq: LUNG) announced the publication of CONVERT Trial results for its AeriSeal System, showing 75.8% of patients with severe emphysema and collateral ventilation had successful treatment. The study suggests the system could enable subsequent treatment with Zephyr Valves, improving lung function and quality of life. Pulmonx is now conducting the CONVERT II Pivotal Trial to support a U.S. FDA Premarket Approval application for the AeriSeal System.

$LUNGMed

Pulmonx reports trial results for emphysema treatment system

Pulmonx (LUNG) reported CONVERT Trial results for its AeriSeal System in severe emphysema patients, showing 75.8% success in converting collateral ventilation status. Treated patients achieved 88.9% target lobe volume reduction at 45 days, with improvements in lung function and quality of life. The company is enrolling patients in the CONVERT II Pivotal Trial for U.S. FDA approval.

$AXGNMedAI 8/10

Axogen Advances Prostate Market Launch, Citing $754 Million U.S. TAM

Axogen plans to launch a prostate-market product, targeting a $754M U.S. market. The company estimates 110,000 annual prostatectomy cases with a $7,000 per-procedure price. Axogen's COAPT technique, using Avance nerve allograft, has shown 80% of patients with better-than-expected erectile function after six months. 88% of surveyed patients expressed interest in the procedure.